/
We are a drug discovery and development company researching two core technologies: Targeted Peptide Technology, or TPT, which is currently our main focus, and Metabolic Disruption Technology, or MDT, which is our secondary focus. Our research indicates that our TPT therapies may be useful in treating autoimmune diseases, or diseases that trigger the body s immune system when doing so is not nec…
$0.52
$0.13 (-20.00%)
EOD Jun 24, 2026 · Twelve Data
Negative free cash flow of -$2M. The business is consuming cash, not generating it.
6.1x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$4M
▲ +16.6% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
-$858K
▼ -84.0% YoY
Op. Cash Flow (TTM)
-$858K
▼ -84.0% YoY
Net Debt
-$23K
Net Cash Position
Cash & Equiv.
$23K
Continue Research